FDA inspection
McNeil PPC Inc.: FDA inspection ending May 24, 2006
FDA inspection 426909 · No Action Indicated (NAI) · Parsippany, NJ
Key facts
| Inspection ID | 426909 |
|---|---|
| Firm | McNeil PPC Inc. |
| FEI number | 2211583 |
| Address | 100 Jefferson Rd |
| City | Parsippany |
| State | NJ |
| ZIP | 07054 |
| Fiscal year | 2006 |
| Inspection end date | May 24, 2006 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data